Yo! Technology. What is it all about?

We'll either figure out if the health of humankind can be improved to the point that we could keep people in sort of a 30, 40-year-old state almost forever.

But I use that word very, very, you know, indefinitely or for a very long period of time, or if there are still so many things we don't understand about the biology, that we can just slow down the clock, but we can't reverse it.

Hello, and... Hello and welcome to Danny in the Valley, your weekly dispatch from behind the scenes and inside the minds of the top people in tech.

I am your host, Danny Fortson, the West Coast correspondent for the Sunday Times.

And this week, we're going to shift gears.

Because, of course, last week we talked about designer babies.

This week, living forever, ish.

So on the program, we have James, I'm going to say this wrong, probably Pyer, P-E-Y-E-R, payer perhaps. He's a stem cell biologist and co-founder

of Cambrian Biopharma, whose last name I should have asked how you pronounce it before. I got on

this podcast, my bad. And Cambrian is a longevity-focused biotech kind of holding company that

last month raised $ million bucks to make some

very big bets on treatments and medicines that James reckons will completely change what it means

to age.

You guys will find this fascinating, trust me.

So before we get into the conversation, just to give you a bit of context, the core idea

here upon which kind of Cambrian is founded is that age itself is a disease that can be treated like any other.

We've talked about this kind of concept before with other guests we've had on here like Laura Deming and others.

But just as a refresher, the idea, this idea was not long

ago seen as kind of crazy or fringe, certainly in kind of academic scientific circles.

But it's really gained traction in recent years as more and more research has been done into

kind of the underlying biological processes of aging, specifically the idea that, say, Alzheimer's may share some of the same

...